RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)
This study tests whether a weekly injection called pemvidutide can help improve liver health in people with alcohol-associated liver disease. Participants will receive either pemvidutide or a placebo (inactive treatment) once per week and will be monitored to see how well the treatment works and how safe it is.
Key Objective:The trial is testing whether pemvidutide can reduce liver damage and improve liver function in patients with alcohol-associated liver disease.
Who to Consider:People with alcohol-associated liver disease who are interested in exploring a new injectable treatment option should consider enrolling.
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in subjects with ALD. * Pemvidutide: 2.4 mg SC once weekly * Placebo: Placebo SC once weekly
Eligibility Criteria
Inclusion Criteria: 1. Male or female ages 18 to 75 years, inclusive 2. Overweight or obesity, defined as BMI ≥ 25 kg/m2 3. History of alcohol misuse for the prior 3 years, with an alcohol intake ≥ 50 grams per day for males and ≥ 40 grams per day for females on average in the past year 4. Liver stiffness of 10.0-18.5 kPa by VCTE, inclusive Exclusion Criteria: 1. Presence of clinically significant alcohol withdrawal symptoms, defined as CIWA-Ar score ≥ 10 at screening and/or prior to randomization 2. History of hospitalization for alcohol intoxication or alcohol withdrawal within the past year 3. History of seizures related to alcohol within the past year 4. History and/or current DSM-5 diagnosis of schizophrenia, bipolar disorder, psychotic disorder, or another severe psychiatric disorder, unless documented as well-controlled by the Investigator for at least 6 months prior to screening and cleared by the Medical Monitor